Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia
Citations: 27
Gemfibrozil helps reduce cholesterol and triglycerides (fatty acids) in the blood
In addition, gemfibrozil exhibited somewhat smaller inhibitory effects on CYP2C19 and CYP1A2 activities, with K (IC 50) values of 24 (47) μM and 82 (136) μM
avoid combo if also combined w/ strong CYP3A4 and P-gp inhibitors; otherwise, caution advised: combo may incr
The effects of the gemfibrozil-itraconazole combination on the pharmacokinetics of montelukast did not differ from those of gemfibrozil alone
In vitro, gemfibrozil is a more potent inhibitor of CYP2C9 than of CYP2C8
Repaglinide is an insulin secretagogue used in the treatment of type 2 diabetes and a drug interaction with gemfibrozil, with or without itraconazole, has been reported []
Rifampicin competitively inhibits both CYP2C8 and CYP3A4, which can counteract its inducing effect in humans
Gemfibrozil competitive inhibition of CYP3A4 was de-activated in the representative moderate CYP2C8 inhibitor developed to selectively result in
ETR has the potential for drug-drug interaction (DDI) with
The CYP3A4 inhibitor In human hepatocytes, both fenofibric acid and clofibric acid are inducers of CYP3A4 and CYP2C8
7 The enzyme is highly expressed in the small in a trial of 11 healthy subjects, the effects of the gemfibrozil-itraconazole combination on the
Because gemfibrozil does not inhibit CYP3A4 in vitro, the mechanism of the pharmacokinetic interaction is Gemfibrozil potently inhibits CYP2C9, and its metabolite gemfibrozil-1-O-glu is a mechanism-dependent inhibitor of CYP2C8 which is important for the oxidation of cerivastatin
Lipid-lowering drugs can be involved also in other interactions, including those between enzyme inducers and CYP3A4 substrate statins, as well as those between gemfibrozil and CYP2C8 substrate antidiabetics
doi: 10
When subjects receiving repaglinide were concurrently administered itraconazole (inhibition of CYP3A4) or gemfibrozil, the area under the concentration time curve (AUC) of repaglinide increased by 40% and 8-fold, respectively, compared with repaglinide alone
Gemfibrozil, a potent CYP2C8 inhibitor, increases treprostinil concentrations Gemfibrozil preincubation time-dependently inhibits metabolism of pioglitazone